Innovative COPD therapy to preserve lung health

Our dNerva® Lung Denervation System is a catheter-based system used to treat overactive airways that may help to reduce the frequency and severity of Chronic Obstructive Pulmonary Disease (COPD) exacerbations.

dNerva Targeted Lung Denervation

Procedure Highlights

One-time, outpatient procedure

Whole lung treatment

“Always on” bronchodilation

Lower risk of COPD exacerbations

dNerva Therapy Impact on COPD Patient Outcomes

After 2 Years 2

  • Significantly lower risk of severe exacerbation

After 3 Years 21,22

Observed Clinical Stability:

  • Stable quality of life after treatment
  • Stable lung function after treatment
  • Positive long-term safety profile

COPD Statistics

Clinical and Economic Burden of COPD

According to the CDC, COPD affects more than 16 million Americans.
increase in disease-related hospitalizations over the next 15 years in developed countries.23
COPD is responsible for $50B in annual direct healthcare expense with hospitalizations being the biggest driver of those costs.6,7,8,9
COPD patients from the UK showed a 14X greater risk of death in the year following a severe exacerbation.18

dNerva Lung Denervation System

The dNerva Lung Denervation System is a catheter-based system used to complete a one-time, out-patient, bronchoscopic procedure to disrupt nerve input to and from the lungs to reduce the clinical consequences of neural hyperactivity.

Current Therapies Aren’t Always Enough

Half of Patients on Optimal Medical Therapy Continue to Exacerbate

Prescribed medications are an integral component of managing COPD exacerbations, but optimal drug therapy is not always effective at preventing these exacerbations.10,11

COPD Exacerbations are the Problem.
Be a Part of the Solution.

The AIRFLOW-3 Clinical Trial is the first interventional COPD device trial targeting exacerbation risk reduction in patients on optimal drug therapy.